This discussion has been published as a research paper
TDX-2026-00008
Managing grade 3 immune-related hepatitis from nivolumab: steroid-refractory case
62M on nivolumab for advanced NSCLC (second-line, after carboplatin/pemetrexed). After 4 cycles, AST rose to 680, ALT 720, total bilirubin 3.8. ALP 145. No fever, no abdominal pain.
Workup: hepatitis B/C negative, ANA weakly positive (1:80), smooth muscle antibody negative. Ultrasound shows mild hepatomegaly, no biliary dilatation. CMV/EBV negative.
Started methylprednisolone 2 mg/kg/day 5 days ago. Transaminases have not improved (AST still 520, ALT 580). This meets the definition of steroid-refractory immune-related hepatitis.
Questions:
- Mycophenolate mofetil vs tacrolimus as second-line immunosuppression?
- Role of liver biopsy at this stage?
- Can nivolumab ever be rechallenged after grade 3 hepatitis?
- How do you manage the underlying NSCLC while immunosuppressed?
2 Answers
As a hepatologist, I see these referrals with increasing frequency as checkpoint inhibitor use expands. My approach:
1. Second-line immunosuppression: Mycophenolate mofetil (MMF) 1g BID is my first choice. The ASCO/NCCN guidelines recommend MMF over tacrolimus for steroid-refractory immune hepatitis. However, if transaminases do not improve within 3 to 5 days of MMF, I add tacrolimus (target trough 5 to 8 ng/mL). Think of it as a stepwise escalation rather than an either/or decision.
2. Liver biopsy: Yes, get one now. Biopsy is critical in steroid-refractory cases to confirm the diagnosis and exclude other etiologies. The histologic pattern of checkpoint-inhibitor hepatitis (lobular hepatitis with mixed infiltrate, prominent CD8+ T cells) differs from autoimmune hepatitis (interface hepatitis, plasma cell-rich) and can guide treatment intensity. I have seen two cases where biopsy revealed drug-induced liver injury from concurrent medications rather than true immune hepatitis.
3. Rechallenge: For grade 3 hepatitis, rechallenge with the same checkpoint inhibitor is generally not recommended. The recurrence rate is approximately 25 to 30% based on pooled analyses. If the patient has no alternative systemic therapy options, rechallenge with a different checkpoint inhibitor class (e.g., switching from anti-PD1 to anti-CTLA4) under close hepatology monitoring has been reported, but data is limited.
4. NSCLC management: This is the hardest part. While immunosuppressed, the patient cannot receive checkpoint inhibitors. Discuss with the oncology team about chemotherapy options (docetaxel, gemcitabine) as a bridge until hepatitis resolves and immunosuppression is tapered.